Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung

Japanese Journal of Clinical Oncology

Volumn 41, Issue 7, 2011, Pages 897-901

  Yoshida, Hiroshi ^a   Sekine, Ikuo ^a   Tsuta, Koji ^a   Horinouchi, Hidehito ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Kubota, Kaoru ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Amrubicin; Chemotherapy; Large cell neuroendocrine carcinoma; Second line

Indexed keywords

ALANINE AMINOTRANSFERASE; AMRUBICIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; CISPLATIN; CREATININE; DOCETAXEL; ETOPOSIDE; IRINOTECAN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; HYPERKALEMIA; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; INFECTION; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CARCINOMA; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SMOKING; STOMATITIS; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79960074875     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr065     Document Type: Article

References (20)

1. Hammond ME, Sause WT. Large cell neuroendocrine tumors of the lung. Clinical significance and histopathologic definition. Cancer 1985;56:1624-9.
2. Warren WH, Gould VE, Faber LP, Kittle CF, Memoli VA. Neuroendocrine neoplasms of the bronchopulmonary tract. A classification of the spectrum of carcinoid to small cell carcinoma and intervening variants. J Thorac Cardiovasc Surg 1985;89:819-25.
3. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB, Jr., Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529-53.
4. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-44.
5. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001;91:1992-2000.
6. Takei H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002;124:285-92.
7. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin ncol 2006;24:70-6.
8. Yamazaki S, Sekine I, Matsuno Y, Takei H, Yamamoto N, Kunitoh H, et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to isplatin-based chemotherapy. Lung Cancer 2005;49:217-23.
9. Fujiwara Y, Sekine I, Tsuta K, Ohe Y, Kunitoh H, Yamamoto N, et al. Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol 2007;37:482-6.
10. Yana T, Negoro S, Takada M, Yokota S, Takada Y, Sugiura T, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:253-8.
11. Sawa T, Yana T, Takada M, Sugiura T, Kudoh S, Kamei T, et al. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial. Invest New Drugs 2006;24:151-8.
12. Takeda K, Takifuji N, Negoro S, Furuse K, Nakamura S, Takada Y, et al. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:377-83.
13. Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448-53.
14. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010;28:2598-603.
15. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401-6.
16. Kaneda H, Okamoto I, Hayashi H, Yoshioka H, Miyazaki M, Kudoh S, et al. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401). J Thorac Oncol 2010;5:105-9.
17. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological Typing of Lung and Pleural Tumors. Berlin: Springer 1999.
18. Goldstraw P. International Association for the Study of Lung Cancer. Staging Handbook in Thoracic Oncology. Orange Park: Editorial Rx Press 2009.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J atl Cancer Inst 2000;92:205-16.
20. Armitage P, Berry G, Matthews J. Survival analysis. In: Armitage P, Berry G, Matthews J, editors. Statistical Methods in Medical Research, 4th edn. xford: Blackwell Science 2002;568-90.